UBS AM
FLGT icon

UBS AM’s Fulgent Genetics FLGT Stock Holding History

UBS AM’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$924K Sell
45,020
-56,283
-56% -$954K ﹤0.01% 2368
2026
Q1 		$1.61M Buy
101,303
+1,007
+1% +$21.9K ﹤0.01% 2140
2025
Q4 		$2.63M Buy
100,296
+42,953
+75% +$1.11M ﹤0.01% 1767
2025
Q3 		$1.3M Sell
57,343
-44,495
-44% -$916K ﹤0.01% 1918
2025
Q2 		$2.02M Buy
101,838
+34,782
+52% +$678K ﹤0.01% 2133
2025
Q1 		$1.13M Buy
67,056
+16,402
+32% +$279K ﹤0.01% 2254
2024
Q4 		$936K Buy
50,654
+5,986
+13% +$117K ﹤0.01% 2389
2024
Q3 		$971K Buy
44,668
+5,898
+15% +$132K ﹤0.01% 2412
2024
Q2 		$761K Buy
38,770
+15,301
+65% +$319K ﹤0.01% 2494
2024
Q1 		$509K Buy
23,469
+3,285
+16% +$81.6K ﹤0.01% 2280
2023
Q4 		$584K Hold
20,184
– – ﹤0.01% 2269
2023
Q3 		$540K Buy
20,184
+1,945
+11% +$66.4K ﹤0.01% 2262
2023
Q2 		$569K Hold
18,239
– – ﹤0.01% 2270
2023
Q1 		$569K Sell
18,239
-5,057
-22% -$163K ﹤0.01% 2270
2022
Q4 		$694K Buy
23,296
+2,572
+12% +$92K ﹤0.01% 2038
2022
Q3 		$790K Sell
20,724
-745
-3% -$37.3K ﹤0.01% 2104
2022
Q2 		$1.17M Sell
21,469
-4,416
-17% -$243K ﹤0.01% 1869
2022
Q1 		$1.62M Buy
25,885
+231
+0.9% +$15.2K ﹤0.01% 1901
2021
Q4 		$2.58M Buy
25,654
+5,669
+28% +$498K ﹤0.01% 1753
2021
Q3 		$1.8M Sell
19,985
-4,134
-17% -$376K ﹤0.01% 1885
2021
Q2 		$2.22M Buy
24,119
+3,056
+15% +$244K ﹤0.01% 1796
2021
Q1 		$2.04M Sell
21,063
-137
-0.6% -$14.1K ﹤0.01% 1734
2020
Q4 		$1.1M Buy
+21,200
New +$886K ﹤0.01% 1939

Other funds holding FLGT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS AM's FLGT Position: Q2 2026 in Review

UBS AM reduced its Fulgent Genetics (FLGT) stake by 56% in Q2 2026, selling an estimated $954K and leaving 45,020 shares worth $924K. The position accounts for ﹤0.01% of the portfolio, ranked #2368.

UBS AM first reported a position in FLGT in Q4 2020 and has held it in 23 quarters since. The position peaked at $2.63M in Q4 2025. 142 funds tracked by Wall St. Rank hold FLGT as of Q2 2026.

  • UBS AM held 45,020 shares of Fulgent Genetics worth $924K as of Q2 2026.
  • UBS AM sold 56,283 Fulgent Genetics shares in Q2 2026, an estimated $954K.
  • Fulgent Genetics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #2368 holding.
  • UBS AM first reported a position in Fulgent Genetics in Q4 2020 and has held it in 23 quarters since.
  • UBS AM's Fulgent Genetics position peaked at $2.63M in Q4 2025.
  • 142 funds tracked by Wall St. Rank held Fulgent Genetics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.